Sentinel node biopsy: an in depth appraisal.
Sentinel node biopsy (SNB) in primary breast cancer has been taken-up widely to avoid the morbidity attributable to axillary node clearance (ANC). Currently many issues surrounding SNB are undecided. This review summarises why some form of axillary surgery is required and presents data on all aspects of SNB including methodology, clinical results and problems that may delay the introduction of SNB as best practice for all patients with primary breast cancer. There is no long or medium term data relating to the consequences of replacing ANC with SNB, but the mechanisms and probable magnitude of both beneficial and detrimental effects are estimated. A low level of false negative results are inherent to the technique but it is demonstrated that SNB is likely to have an only marginal (0.6%) effect on survival that would be undetectable by clinical trials. Patient sub-groups particularly likely to benefit from SNB are identified.
Strickland
Andrew H
AH
Department of Medical Oncology, Monash Medical Centre, East Bentleigh, Vic. 3165, Australia.
Beechey-Newman
Nicolas
N
Steer
Christopher B
CB
Harper
Peter G
PG
D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D003951:Diagnostic Errors; D003952:Diagnostic Imaging / Q000379:methods; D005260:Female; D006801:Humans; D011237:Predictive Value of Tests; D021701:Sentinel Lymph Node Biopsy / Q000379:methods* / Q000592:standards